Core Viewpoint - Fuxiang Pharmaceutical (300497.SZ) expects a loss of 39 million to 57 million yuan in 2025, with a non-recurring loss of 69 million to 87 million yuan, and operating revenue projected between 1.15 billion to 1.25 billion yuan [1] Group 1: Business Performance - The company anticipates significant improvement in overall operating performance driven by the synergistic development of its three main business segments in 2025 [1] - The lithium battery electrolyte additive business is expected to benefit from the continuous growth in demand for power batteries and the rapid explosion in energy storage battery demand, leading to a substantial increase in prices of VC and FEC products in Q4 [1] - In the pharmaceutical manufacturing sector, despite intense market competition, the decline in prices of key raw materials such as 6-APA for core products like Tazobactam and Sulbactam is expected to enhance the gross margin of the pharmaceutical business [1] Group 2: Financial Projections - The projected operating revenue for 2025 is estimated to be between 1.15 billion and 1.25 billion yuan [1] - The expected net profit attributable to shareholders of the listed company is anticipated to significantly reduce losses year-on-year due to the improved profitability of the aforementioned business segments [1]

证券日报网讯 1月26日，美诺华发布公告称，公司2025年度实现归属于母公司所有者的净利润预计为 10，000.00万元到12，300.00万元，与上年同期相比增加3，319.34万元到5，619.34万元，同比增加 49.69%到84.11%。 （编辑 王雪儿） ...

Core Viewpoint - Fuxiang Pharmaceutical has announced its performance forecast for the year 2025, indicating a projected revenue decline compared to the previous year, along with expected losses in net profit [1] Group 1: Revenue Forecast - The company expects its operating revenue for 2025 to be between 1.15 billion and 1.25 billion yuan, compared to 1.17785 billion yuan in the same period last year [1] Group 2: Profit Forecast - The net profit attributable to shareholders is anticipated to be a loss ranging from 39 million to 57 million yuan, an improvement from a loss of 272.1 million yuan in the previous year [1]

证券日报网讯 1月26日，华海药业发布2025年度业绩预减公告称，公司2025年度实现归属于上市公司股 东的净利润预计在22，400万元至33，500万元之间，与上年同期相比将减少约78，398万元到89，498万 元，同比降低约70%到80%。 （编辑 袁冠琳） ...

证券日报网讯 1月26日，国药现代发布公告称，公司2025年实现营业收入9，363，062，749.56元，同比 下降14.40%；归属于上市公司股东的净利润944，379，815.55元，同比下降12.85%。 （文章来源：证券日报） ...

北京商报讯（记者 王寅浩 宋雨盈）1月26日，国药现代发布2025年业绩快报，2025年实现营业总收入 93.63亿元，同比下降14.4%，归属于上市公司股东的净利润为9.44亿元，同比下降12.85%，归属于上市 公司股东的扣除非经常性损益的净利润为8.52亿元，同比下降18.36%。 ...

Core Viewpoint - Fujilai expects a net profit of 62.7 million to 65.1 million yuan for the fiscal year 2025, representing a year-on-year growth of 282.17% to 296.80% [1] Financial Performance - The anticipated impact of non-recurring gains and losses on net profit is approximately 67.6 million yuan, primarily attributed to investment income from financial products and changes in fair value at the end of the period [1]

证券日报网讯1月26日，皓元医药在互动平台回答投资者提问时表示，公司牢牢把握"产业化、全球化、 品牌化"发展战略定力，稳步实施提质增效举措，优化业务布局，合理推进工程建设，为各项业务发展 积势蓄能。公司也成立了战略投资部，未来也将一直保持对市场机会的关注，积极寻找与公司发展战略 比较契合、有价值的优质项目和标的，未来不排除对一些合适的项目进行参股或并购。 ...

Core Viewpoint - Huahai Pharmaceutical (600521.SH) expects a significant decrease in net profit for the fiscal year 2025, projecting a range between 224 million yuan and 335 million yuan, which represents a decline of approximately 70% to 80% compared to the previous year [1] Financial Performance - The company anticipates a reduction in net profit attributable to shareholders of approximately 78.398 million yuan to 89.498 million yuan compared to the same period last year [1]

Core Viewpoint - *ST Shuangcheng (002693.SZ) is expected to turn a profit in 2025, with net profit attributable to shareholders projected between 16 million to 23 million yuan, marking a significant turnaround from losses in the previous year [1] Financial Performance - The company anticipates a total profit growth of 107.53% to 111.30% year-on-year, with net profit attributable to shareholders expected to increase by 120.43% to 129.37% [1] - Revenue is projected to be between 250 million to 290 million yuan [1] Factors Influencing Profit Changes - The company is focusing on international development to counteract domestic drug price declines, leading to steady growth in export sales and advancements in overseas R&D projects [1] - The approval of the U.S. registration application for injectable paclitaxel (albumin-bound) is expected to drive significant revenue growth following its rapid sales post-approval [1] - The absence of fair value loss from Zhongrong Trust financial products, which impacted the previous year's results, and a reduction in asset impairment losses have also contributed to the turnaround [1]